{"id":"oxacillin","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Allergic reactions","drugRate":"10%","severity":"serious"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Angioneurotic edema","drugRate":"reported","severity":"unknown"},{"effect":"Laryngospasm","drugRate":"reported","severity":"unknown"},{"effect":"Bronchospasm","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Vascular collapse","drugRate":"reported","severity":"unknown"},{"effect":"Death","drugRate":"reported","severity":"unknown"},{"effect":"Serum sickness-like symptoms","drugRate":"reported","severity":"unknown"},{"effect":"Fever","drugRate":"reported","severity":"unknown"},{"effect":"Malaise","drugRate":"reported","severity":"unknown"},{"effect":"Myalgia","drugRate":"reported","severity":"unknown"},{"effect":"Arthralgia","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Stomatitis","drugRate":"reported","severity":"unknown"},{"effect":"Black or hairy tongue","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal irritation","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Eosinophilia","drugRate":"reported","severity":"unknown"},{"effect":"Hematuria","drugRate":"reported","severity":"unknown"},{"effect":"Proteinuria","drugRate":"reported","severity":"unknown"},{"effect":"Renal insufficiency","drugRate":"reported","severity":"unknown"},{"effect":"Pseudomembranous colitis","drugRate":"reported","severity":"unknown"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Bone marrow depression","drugRate":"reported","severity":"unknown"}],"contraindications":["Infectious mononucleosis","Kidney disease","Pseudomembranous enterocolitis"]},"trials":[],"_chembl":{"chemblId":"CHEMBL819","moleculeType":"Small molecule","molecularWeight":"401.44"},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T18:35:30.534345","allNames":"bactocill in plastic container","offLabel":[],"timeline":[],"_dailymed":{"setId":"4972ec74-1d9a-de9b-e063-6394a90af786","title":"OXACILLIN INJECTION, POWDER, FOR SOLUTION [ONESOURCE SPECIALTY PHARMA LIMITED]"},"ecosystem":[],"mechanism":{"target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","modality":"Small Molecule"},"_scrapedAt":"2026-03-27T23:59:10.488Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Acute bacterial sinusitis","diseaseId":"acute-bacterial-sinusitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Continuation Therapy for Acute Osteomyelitis","diseaseId":"continuation-therapy-for-acute-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Continuation Therapy for Chronic Osteomyelitis","diseaseId":"continuation-therapy-for-chronic-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of bone","diseaseId":"infection-of-bone","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of skin AND/OR subcutaneous tissue","diseaseId":"infection-of-skin-and/or-subcutaneous-tissue","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Lower respiratory tract infection","diseaseId":"lower-respiratory-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteomyelitis due to Staphylococcus aureus","diseaseId":"osteomyelitis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pharyngitis","diseaseId":"pharyngitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis due to Staphylococcus aureus","diseaseId":"sepsis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sinusitis","diseaseId":"sinusitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal Prosthetic Heart Valve Endocarditis","diseaseId":"staphylococcal-prosthetic-heart-valve-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal endocarditis","diseaseId":"staphylococcal-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal infectious disease","diseaseId":"staphylococcal-infectious-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal meningitis","diseaseId":"staphylococcal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pneumonia","diseaseId":"staphylococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal septicemia","diseaseId":"staphylococcal-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Bronchitis","diseaseId":"staphylococcus-aureus-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Joint Infection","diseaseId":"staphylococcus-aureus-joint-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Urinary Tract Infection","diseaseId":"staphylococcus-aureus-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Epidermidis Urinary Tract Infection","diseaseId":"staphylococcus-epidermidis-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","generics(15)","patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT02701608","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":162},{"nctId":"NCT03248063","phase":"NA","title":"Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-05","conditions":"Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus","enrollment":315},{"nctId":"NCT07186894","phase":"","title":"Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2000-01-01","conditions":"Bacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection","enrollment":5000},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT04563325","phase":"PHASE4","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-09-15","conditions":"Osteomyelitis, Septic Arthritis, Bone Infection","enrollment":180},{"nctId":"NCT06726395","phase":"PHASE4","title":"Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-03-10","conditions":"Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)","enrollment":420},{"nctId":"NCT05929599","phase":"NA","title":"Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Children's Hospital, Vietnam","startDate":"2023-07-05","conditions":"Acute Respiratory Tract Infections, Pneumonia, Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT06728228","phase":"NA","title":"Amnioinfusion for Fetal Renal Failure","status":"RECRUITING","sponsor":"Fetal Care Center, PLLC","startDate":"2024-12-05","conditions":"Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly","enrollment":35},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Staphylococcal Bacteraemia","enrollment":200},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":"Bacterial Vaginosis","enrollment":200},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT06495697","phase":"","title":"Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-07-19","conditions":"Staphylococcus Aureus Infection","enrollment":200},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT06454643","phase":"NA","title":"Gentamicin in Cardiac Surgery","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2020-01-01","conditions":"Cardiac Infection","enrollment":50},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT05578482","phase":"PHASE4","title":"Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis","status":"UNKNOWN","sponsor":"Jacob Pontoppidan Thyssen","startDate":"2022-10-24","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis Flare","enrollment":45},{"nctId":"NCT03632642","phase":"PHASE4","title":"Penicillin Against Flucloxacillin Treatment Evaluation","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2019-07-01","conditions":"Staphylococcus Aureus","enrollment":""},{"nctId":"NCT02334124","phase":"NA","title":"Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-01","conditions":"Cellulitis","enrollment":190},{"nctId":"NCT01876628","phase":"PHASE4","title":"Adjunctive Clindamycin for Cellulitis: C4C Trial.","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2013-10","conditions":"Cellulitis","enrollment":410},{"nctId":"NCT05073627","phase":"PHASE1","title":"The Effect of Dicloxacillin on Oral Absorption of Drugs","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Healthy Volunteers, Drug-drug Interaction","enrollment":12},{"nctId":"NCT04840641","phase":"PHASE1","title":"Flucloxacillin as an Inducer of CYP-enzymes","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2021-03-25","conditions":"Healthy Volunteers, Drug Drug Interaction","enrollment":14},{"nctId":"NCT05106803","phase":"","title":"Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan","status":"COMPLETED","sponsor":"Yarmouk University","startDate":"2019-08-01","conditions":"Bacterial Infections, Antibiotic Resistant Infection, Surgical Site Infection","enrollment":24},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01792804","phase":"PHASE3","title":"Staphylococcus Aureus Bacteremia Antibiotic Treatment Options","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2013-12","conditions":"Staphylococcus Aureus Infection","enrollment":215},{"nctId":"NCT00433342","phase":"PHASE1","title":"The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2006-03","conditions":"Chronic Kidney Disease","enrollment":9},{"nctId":"NCT02208063","phase":"PHASE3","title":"A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial","status":"TERMINATED","sponsor":"Cumberland Pharmaceuticals","startDate":"2014-12","conditions":"Bacteremia","enrollment":121},{"nctId":"NCT04141787","phase":"PHASE4","title":"Ceftriaxone as Home IV for Staph Infections","status":"UNKNOWN","sponsor":"Vancouver Island Health Authority","startDate":"2019-07-11","conditions":"Staphylococcal Infections, Osteomyelitis, CNS Infection","enrollment":310},{"nctId":"NCT04037111","phase":"NA","title":"Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-07-23","conditions":"Major Depressive Disorder, Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT00062647","phase":"PHASE2","title":"Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-08","conditions":"Gram-Positive Bacterial Infections","enrollment":60},{"nctId":"NCT00077675","phase":"PHASE2","title":"Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2004-02","conditions":"Infections, Gram-positive Bacterial","enrollment":201},{"nctId":"NCT00061633","phase":"PHASE2","title":"Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)","status":"COMPLETED","sponsor":"Cumberland Pharmaceuticals","startDate":"2003-06","conditions":"Infections, Gram-Positive Bacterial, Abscess, Burns","enrollment":169},{"nctId":"NCT02365493","phase":"PHASE3","title":"Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection","status":"TERMINATED","sponsor":"Menzies School of Health Research","startDate":"2015-08-26","conditions":"Methicillin-Resistant Staphylococcus Aureus","enrollment":358},{"nctId":"NCT02993575","phase":"","title":"Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-06-01","conditions":"Bacterial Infections","enrollment":30},{"nctId":"NCT01104662","phase":"PHASE4","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-04-19","conditions":"Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment","enrollment":92},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT02983890","phase":"PHASE1","title":"Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.","status":"COMPLETED","sponsor":"Per Damkier","startDate":"2016-10-06","conditions":"Healthy","enrollment":12},{"nctId":"NCT00428844","phase":"PHASE2","title":"Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-06-26","conditions":"Osteomyelitis","enrollment":75},{"nctId":"NCT01191840","phase":"PHASE2","title":"Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2011-02","conditions":"Bacteremia","enrollment":509},{"nctId":"NCT02032654","phase":"PHASE4","title":"Duration of ANtibiotic Therapy for CEllulitis","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-08-26","conditions":"Cellulitis, Erysipelas","enrollment":151},{"nctId":"NCT00358371","phase":"PHASE1","title":"Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Infections, Bacterial","enrollment":24},{"nctId":"NCT03120663","phase":"","title":"Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-11-30","conditions":"Surgery","enrollment":120},{"nctId":"NCT02922686","phase":"PHASE4","title":"Penicillin for the Emergency Department Outpatient Treatment of CELLulitis","status":"UNKNOWN","sponsor":"Royal College of Surgeons, Ireland","startDate":"2016-12","conditions":"Cellulitis, Wound Infection, Abscess","enrollment":414},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":"Osteomyelitis","enrollment":""},{"nctId":"NCT01875263","phase":"PHASE3","title":"Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.","status":"TERMINATED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-05","conditions":"Staphylococcus","enrollment":1},{"nctId":"NCT01626560","phase":"PHASE4","title":"The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin","status":"COMPLETED","sponsor":"Hospital Universitario Evangelico de Curitiba","startDate":"2012-07","conditions":"Cellulitis","enrollment":20},{"nctId":"NCT00423982","phase":"PHASE4","title":"Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2006-04","conditions":"Prosthesis-related Infections, Staphylococcal Infections","enrollment":100},{"nctId":"NCT01184872","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Infections","enrollment":120},{"nctId":"NCT01166932","phase":"PHASE4","title":"Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2005-04","conditions":"Community-Acquired Pneumonia","enrollment":104},{"nctId":"NCT00037050","phase":"PHASE3","title":"Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-04","conditions":"Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia","enrollment":739},{"nctId":"NCT00716183","phase":"PHASE2, PHASE3","title":"Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2008-07","conditions":"Mastitis","enrollment":300},{"nctId":"NCT00885300","phase":"NA","title":"Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2008-01","conditions":"Double Lumen Infection, Hemodialysis","enrollment":100},{"nctId":"NCT00518076","phase":"","title":"Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2006-09","conditions":"Staphylococcal Infections","enrollment":""},{"nctId":"NCT00405158","phase":"NA","title":"Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding","status":"COMPLETED","sponsor":"Karlstad University","startDate":"2002-01","conditions":"Mastitis","enrollment":210},{"nctId":"NCT00129688","phase":"NA","title":"Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children","status":"COMPLETED","sponsor":"Khon Kaen University","startDate":"2002-04","conditions":"Neutropenia, Cancer, Fever","enrollment":166}],"_emaApprovals":[],"_faersSignals":[{"count":88,"reaction":"DRUG INEFFECTIVE"},{"count":68,"reaction":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS"},{"count":63,"reaction":"ACUTE KIDNEY INJURY"},{"count":61,"reaction":"PYREXIA"},{"count":56,"reaction":"RASH"},{"count":46,"reaction":"OFF LABEL USE"},{"count":43,"reaction":"DRUG INTERACTION"},{"count":43,"reaction":"TOXIC EPIDERMAL NECROLYSIS"},{"count":41,"reaction":"PNEUMONIA"},{"count":41,"reaction":"RENAL FAILURE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_approvalHistory":[{"date":"20200720","type":"ORIG","sponsor":"FRESENIUS KABI USA","applicationNumber":"ANDA206198"},{"date":"20200727","type":"ORIG","sponsor":"FRESENIUS KABI USA","applicationNumber":"ANDA206199"},{"date":"19891026","type":"ORIG","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20020823","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20150106","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20000612","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20121121","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"19930405","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20111013","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20140219","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20040317","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"19990202","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"19911219","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20130419","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20170224","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20080417","type":"SUPPL","sponsor":"BAXTER HLTHCARE","applicationNumber":"NDA050640"},{"date":"20130426","type":"SUPPL","sponsor":"EUGIA PHARMA SPECLTS","applicationNumber":"ANDA201538"},{"date":"20130118","type":"ORIG","sponsor":"EUGIA PHARMA SPECLTS","applicationNumber":"ANDA201538"},{"date":"20180801","type":"SUPPL","sponsor":"EUGIA PHARMA SPECLTS","applicationNumber":"ANDA201539"},{"date":"20130426","type":"SUPPL","sponsor":"EUGIA PHARMA SPECLTS","applicationNumber":"ANDA201539"},{"date":"20130118","type":"ORIG","sponsor":"EUGIA PHARMA SPECLTS","applicationNumber":"ANDA201539"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":5933,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":15,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Apothecon","Elkins Sinn","Eugia Pharma Speclts","Fresenius Kabi Usa","Glaxosmithkline","Hospira","Istituto Bio Ita Spa","Onesource Specialty","Piramal Critical","Sagent Pharms","Sandoz","Teva","Watson Labs Inc","Wockhardt Bio Ag"],"phase":"marketed","status":"approved","brandName":"Bactocill In Plastic Container","genericName":"OXACILLIN","companyName":"Apothecon","companyId":"","modality":"Small molecule","firstApprovalDate":"1971","aiSummary":"Bactocill In Plastic Container (Oxacillin) is a penicillin-class antibacterial medication originally developed by Sandoz and currently owned by Apothecon. It targets prostaglandin G/H synthase 1 and is used to treat various bacterial infections, including those caused by Staphylococcus aureus. The medication is available as a generic product, with 15 manufacturers, and is off-patent. Key safety considerations include its short half-life of 0.7 hours and limited bioavailability of 33%. It is FDA-approved for several indications, including acute bacterial sinusitis and osteomyelitis.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}